Press Releases

SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Doximity, the professional medical network, today published the first comprehensive

TOKYO and BOTHELL, Wash., July 16, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa

BOSTON, July 16, 2019 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University-Ma

WASHINGTON, July 16, 2019 /PRNewswire/ -- Medicomp Systems, a physician-driven provider of clinically contextual patient data solutions, announced today that the United States Paten

RESEARCH TRIANGLE PARK, N.C., July 16, 2019 /PRNewswire/ -- Pappas Capital, a leading investor in early-stage life sciences companies, today announced the promotion of Kyle Rasbach, PhD, PharmD to a Managing Partner of Pappas Ventures, the firm's venture capital business. In his new role, Dr. Rasbach will help to oversee Pappas Ventures an

GERMANTOWN, Md., July 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17, 2019

LAVAL, QC, July 16, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the United State

Stock Market SymbolsGIB (NYSE)GIB.A (TSX)www.cgi.com/newsroom FAIRFAX, VA, July 16, 2019 /PRNewswire/ - CGI (NYSE: GIB) (TS

JERUSALEM, Israel, July 16, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is proud to announce today the results of its previously announced rights offering. The Company has received subscriptions from existing shareholders for all the offered American Depositary Shares ("ADSs") and ordinary shares, being a total of 3,057,466 ADSs and 18,

GREENSBORO, N.C., July 16, 2019 /PRNewswire/ -- MutantDx announces the awarding of patents for their ultra-sensitive Liquid Biopsy technology by the United States and European Patent Offices. This technology can identify and confirm the minute amounts of DNA cancer mutations liberated into the blood stream, while virtually